GE Healthcare Partners with Fujitsu to Develop AI for Spotting Brain Aneurysms
|
By HospiMedica International staff writers Posted on 22 Aug 2019 |
GE Healthcare (Chicago, IL, USA) has entered into a research collaboration with Fujitsu Australia (Tokyo, Japan) to diagnose and monitor brain aneurysms on scans faster and more efficiently by using artificial intelligence (AI). The project has already received a Cooperative Research Centres Projects (CRC-P) grant of AUD 2.1 million from the Department of Industry, Innovation and Science.
Fujitsu will lead the initiative and leverage its AI and digital solutions capability through its dedicated innovation team in Australia. GE Healthcare will contribute through its leading medical imaging technology. Fujitsu will apply AI methods to images of the brain generated by GE’s Revolution CT scanner, and use a specifically trained algorithm to look for abnormalities and aneurysms. Macquarie University and Macquarie Medical Imaging will provide clinical expertise for the development and testing of the technology. Initially the project will focus on refining the technology with a view to creating a fully commercialized solution that will be distributed initially through radiology practices in Australia and eventually on a worldwide basis.
The outcomes from this project are anticipated to include the development and validation of an AI algorithm capable of highlighting blood vessels within the circle of Willis, an arterial ring sited at the base of the brain that may have one or more aneurysms. This technology will also allow the tracking of identified aneurysms over time, providing radiologists with a valuable diagnostic support tool and patients with greater peace of mind that known aneurysms are being effectively monitored over the long-term. A second element to the project will include a planning tool for surgical (stent) intervention. This tool will use fluid dynamic modeling to predict the risk of aneurysm rupture.
“We are pleased to be part of this important ‘co-creation’ initiative that leverages the strengths of each of our partners, as well as Fujitsu’s experience in AI to have a positive impact on peoples’ lives,” said Mike Foster, Chief Executive Officer of Fujitsu Australia and New Zealand. “AI in particular has the capability to make our daily lives more comfortable and contribute to solving difficult problems such as detecting serious medical issues early and allowing more timely treatment intervention. This is an excellent demonstration of Fujitsu’s commitment to creating human-centric innovation together with our customers and partners to build a trusted future where everyone can feel safe.”
“As the consequences of brain aneurysm rupture are often fatal, effective and expedient detection is crucial. Unfortunately screening and monitoring takes time and specialist expertise not afforded by every radiology practice,” said Matt Tucker, President and CEO GE Healthcare Australia & New Zealand. “The application of AI can give doctors better insights more quickly and produce fewer variable results. We are proud to be part of this program that will transform brain aneurysm diagnosis and improve patient outcomes.”
“This is an excellent example of the MQ Health model of “Heal, Learn and Discover” in action with industry. Macquarie University, with its own hospital and clinical expertise is well placed to actively contribute to the development of applied medical innovations and welcomes the opportunity to work with leading information technology, healthcare and diagnostic companies such as Fujitsu, GE Healthcare and Macquarie Medical Imaging,” said Professor Patrick McNeil, Deputy Vice Chancellor Medicine and Health and Executive Dean, Faculty of Medicine and Health Sciences, Macquarie University.
Fujitsu will lead the initiative and leverage its AI and digital solutions capability through its dedicated innovation team in Australia. GE Healthcare will contribute through its leading medical imaging technology. Fujitsu will apply AI methods to images of the brain generated by GE’s Revolution CT scanner, and use a specifically trained algorithm to look for abnormalities and aneurysms. Macquarie University and Macquarie Medical Imaging will provide clinical expertise for the development and testing of the technology. Initially the project will focus on refining the technology with a view to creating a fully commercialized solution that will be distributed initially through radiology practices in Australia and eventually on a worldwide basis.
The outcomes from this project are anticipated to include the development and validation of an AI algorithm capable of highlighting blood vessels within the circle of Willis, an arterial ring sited at the base of the brain that may have one or more aneurysms. This technology will also allow the tracking of identified aneurysms over time, providing radiologists with a valuable diagnostic support tool and patients with greater peace of mind that known aneurysms are being effectively monitored over the long-term. A second element to the project will include a planning tool for surgical (stent) intervention. This tool will use fluid dynamic modeling to predict the risk of aneurysm rupture.
“We are pleased to be part of this important ‘co-creation’ initiative that leverages the strengths of each of our partners, as well as Fujitsu’s experience in AI to have a positive impact on peoples’ lives,” said Mike Foster, Chief Executive Officer of Fujitsu Australia and New Zealand. “AI in particular has the capability to make our daily lives more comfortable and contribute to solving difficult problems such as detecting serious medical issues early and allowing more timely treatment intervention. This is an excellent demonstration of Fujitsu’s commitment to creating human-centric innovation together with our customers and partners to build a trusted future where everyone can feel safe.”
“As the consequences of brain aneurysm rupture are often fatal, effective and expedient detection is crucial. Unfortunately screening and monitoring takes time and specialist expertise not afforded by every radiology practice,” said Matt Tucker, President and CEO GE Healthcare Australia & New Zealand. “The application of AI can give doctors better insights more quickly and produce fewer variable results. We are proud to be part of this program that will transform brain aneurysm diagnosis and improve patient outcomes.”
“This is an excellent example of the MQ Health model of “Heal, Learn and Discover” in action with industry. Macquarie University, with its own hospital and clinical expertise is well placed to actively contribute to the development of applied medical innovations and welcomes the opportunity to work with leading information technology, healthcare and diagnostic companies such as Fujitsu, GE Healthcare and Macquarie Medical Imaging,” said Professor Patrick McNeil, Deputy Vice Chancellor Medicine and Health and Executive Dean, Faculty of Medicine and Health Sciences, Macquarie University.
Latest AI News
- Machine Learning Approach Enhances Liver Cancer Risk Stratification
- New AI Approach Monitors Brain Health Using Passive Wearable Data
- AI Tool Maps Early Risk Patterns in Bloodstream Infections
- AI Model Identifies Rare Endocrine Disorder from Hand Images
- AI Tool Promises to Reduce Length of Hospital Stays and Free Up Beds
- Machine Learning Model Cuts Canceled Liver Transplants By 60%
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read moreCritical Care
view channel
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
Pulmonary hypertension is a progressive, life‑threatening disease that is frequently missed early because symptoms such as dyspnea are nonspecific and diagnostic delays can exceed two years.... Read moreSurgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel







